Surmodics (SRDX)
(Delayed Data from NSDQ)
$38.20 USD
-0.17 (-0.44%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.20 USD
-0.17 (-0.44%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Zacks News
CVS Health Rides on Aetna Synergy, PBM Selling Season Modest
by Zacks Equity Research
With regard to its 2019 PBM selling season, CVS Health (CVS) notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds.
Here's Why Investors Should Hold DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.
Medidata's (MDSO) Margins Under Pressure, Competition Rife
by Zacks Equity Research
Medidata (MDSO) suffers from cutthroat competition in the clinical trial solutions market at the moment.
Will Surmodics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Surmodics.
Here's Why Investors Should Buy Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.
Baxter's Acute Therapies Profile Strong, Competition Rife
by Zacks Equity Research
Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.
Here's Why Investors Should Retain AmerisourceBergen Stock
by Zacks Equity Research
AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
A series of software upgrades is likely to provide Accuray (ARAY) a competitive edge in the radiation-oncology space.
Here's Why You Should Buy Wright Medical (WMGI) Stock Now
by Zacks Equity Research
A growing orthopedic market and strong international expansion make Wright Medical (WMGI) a promising investment pick at the moment.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.
QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark
by Zacks Equity Research
QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.
Here's Why You Should Hold Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical's (ISRG) solid exposure to robotics & medical mechatronics is commendable. Its robot-based da Vinci Surgical System for minimally-invasive surgery is an added positive.
IDEXX (IDXX) Q4 Earnings Top Estimates, Raises '19 EPS View
by Zacks Equity Research
IDEXX's (IDXX) Q4 top line was driven by strong global gains in CAG Diagnostics recurring revenues along with expansion in global premium instrument installed base.
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Meet
by Zacks Equity Research
Cardiovascular Systems (CSII) benefits from year-over-year growth in both Coronary and peripheral device segments.
ABIOMED (ABMD) Q3 Earnings Beat, Impella Maintains Momentum
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella sees a solid Q3; fiscal 2019 outlook raised.
Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid
by Zacks Equity Research
Surmodics' (SRDX) fiscal Q1 sees solid contributions from all segments.
AmerisourceBergen (ABC) Beats on Q1 Earnings, Trims EPS View
by Zacks Equity Research
AmerisourceBergen (ABC) registers solid growth at the Pharmaceutical Distribution segment and the World Courier business in first-quarter fiscal 2019.
Baxter's (BAX) Earnings, Revenues Beat Estimates in Q4
by Zacks Equity Research
Baxter (BAX) gains from the Renal Care and Advanced Surgery units in fourth-quarter 2018; Clinical Nutrition revenues soft.
SurModics (SRDX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 1300.00% and 17.68%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio
by Zacks Equity Research
The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining strength from the In Vitro Diagnostics (IVD) unit. The segment is a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.
Medical Products Industry Gathering Steam: 3 Stocks to Buy
by Nabaparna Bhattacharya
The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.
Surmodics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Surmodics, Inc. (SRDX) has been struggling lately, but the selling pressure may be coming to an end soon.
Here's Why You Should Invest in Veeva Systems (VEEV) Now
by Zacks Equity Research
Veeva Systems' (VEEV) focus on cloud-based systems like Veeva Vault makes it a solid pick.